top of page

WOA Publications

McClung MR, Rothman MS, Lewiecki EM, Hanley DA, Harris ST, Miller PD, Kendler DL.The role of osteoanabolic agents in the management of patients with osteoporosis.Postgrad Med. 2022 Aug;134(6):541-551. doi: 10.1080/00325481.2022.2069582

Lewiecki EM, Kendler DL, Davison KS, Hanley DA, Harris ST, McClung MR, Miller PD. Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis. Am J Med. 2019 May 29. pii: S0002-9343(19)30441-3. doi: 10.1016/j.amjmed.2019.04.044. [Epub ahead of print] Review

Hanley DA, McClung MR, Davison KS, Dian L, Harris ST, Miller PD, Lewiecki EM, Kendler DL; Writing Group for the Western Osteoporosis Alliance. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies. Am J Med. 2017 Jul;130(7):862.e1-862.e7. doi: 10.1016/j.amjmed.2017.03.002. Epub 2017 Mar 27. Review. PubMed PMID: 28359721.

Kendler DL, Bauer DC, Davison KS, Dian L, Hanley DA, Harris ST, McClung MR, Miller PD, Schousboe JT, Yuen CK, Lewiecki EM. Vertebral Fractures: Clinical Importance and Management. Am J Med. 2016 Feb;129(2):221.e1-10. doi: 10.1016/j.amjmed.2015.09.020. Epub 2015 Oct 30. Review. PubMed PMID: 26524708.

Lewiecki EM, Miller PD, Harris ST, Bauer DC, Davison KS, Dian L, Hanley DA, McClung MR, Yuen CK, Kendler DL. Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis. J Clin Densitom. 2014 Oct-Dec;17(4):490-5. doi:10.1016/j.jocd.2013.09.018. Epub 2013 Oct 25. Review. PubMed PMID: 24206867.

McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013 Jan;126(1):13-20. doi: 10.1016/j.amjmed.2012.06.023. Epub 2012 Nov 20. Review. PubMed PMID: 23177553.

Davison KS, Kendler DL, Ammann P, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, McClung MR, Olszynski WP, Yuen CK. Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond. Am J Med. 2009 Nov;122(11):992-7. doi: 10.1016/j.amjmed.2009.05.018. Review. PubMed PMID: 19854322.

Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005 Aug;26(5):688-703. Epub 2005 Mar 15. Review. PubMed PMID: 15769903.

Olszynski WP, Shawn Davison K, Adachi JD, Brown JP, Cummings SR, Hanley DA,  Harris SP, Hodsman AB, Kendler D, McClung MR, Miller PD, Yuen CK. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther. 2004 Jan;26(1):15-28. Review. PubMed PMID: 14996514.

Papaioannou A, Watts NB, Kendler DL, Yuen CK, Adachi JD, Ferko N. Diagnosis and management of vertebral fractures in elderly adults. Am J Med. 2002 Aug 15;113(3):220-8. Review. PubMed PMID: 12208381.

William M. Drake WM, Kendler DL, Brown JP. Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Clinical Therapeutics 2001;23(4):620-6. Review, PubMed  PMID: 11354395 

bottom of page